title: Evaluation of anticonvulsants for possible use in neuropathic pain.
abstract: Neuropathic pain is a kind of pain related with functional abnormality of neurons. Despite large progress in pharmacotherapy, neuropathic pain is still considered an unmet need. Nowadays, there are few drugs registered for this condition, such as pregabalin, gabapentin, duloxetine, carbamazepine, and lidocaine. Among them, pregabalin, gabapentin and carbamazepine are well known antiepileptic drugs. Among the group of new antiepileptic drugs, which are addressed to 1% of human world population suffering from seizures, it turned out that 30% of the seizures resistant to pharmacotherapy has not enough market to justify the costs of drug development. Therefore, it is already a phenomenon that researchers turn their projects toward a larger market, related with possible similar mechanism. Anticonvulsant mechanism of action is in the first place among primary indications for drugs revealing potential analgesic activity. Therefore, many drug candidates for epilepsy, still in preclinical stage, are being evaluated for activity in neuropathic pain. This review is focusing on antiepileptic drugs, which are evaluated for their analgesic activity in major tests related with neuropathic pain. Relation between structure, mechanism of action and result in tests such as the Chung model (spinal nerve ligation SNL), the Bennett model (chronic constriction injury of sciatic nerve CCI) and other tests are considered. The first examples are carbamazepine, gabapentin, and lacosamide as drugs well established in epilepsy market as well as drug candidates such as valnoctamide, and other valproic acid derivatives, novel biphenyl pyrazole derivatives, etc. Moreover, clinical efficacy related with listed animal models has been discussed.
authors.affiliation: Department of Bioorganic Chemistry, Jagiellonian University Medical College, 30-688 Krakow, Poland. awaszkie@cm-uj.krakow.pl
authors.forename: A M
authors.initials: AM
authors.lastname: Waszkielewicz
authors.forename: A
authors.initials: A
authors.lastname: Gunia
authors.forename: K
authors.initials: K
authors.lastname: Słoczyńska
authors.forename: H
authors.initials: H
authors.lastname: Marona
mesh_terms: D000927:Anticonvulsants / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018691:Excitatory Amino Acid Antagonists / Q000737:chemistry / Q000627:therapeutic use; D058787:GABA-A Receptor Antagonists / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D007473:Ion Channels / Q000737:chemistry / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000737:chemistry / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000737:chemistry / Q000378:metabolism; D009437:Neuralgia / Q000188:drug therapy*
chemical_list: D000927:Anticonvulsants; D018691:Excitatory Amino Acid Antagonists; D058787:GABA-A Receptor Antagonists; D007473:Ion Channels; D008562:Membrane Glycoproteins; D009419:Nerve Tissue Proteins; C076414:SV2A protein, human